| scholarly article | Q13442814 |
| P2093 | author name string | Craig J Galbán | |
| Marina Pasca di Magliano | |||
| Meredith A Collins | |||
| Stefanie Galbán | |||
| Filip Bednar | |||
| Yaqing Zhang | |||
| N Volkan Adsay | |||
| Jean-Christophe Brisset | |||
| Sabita Rakshit | |||
| Karen S Flannagan | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Detection of genomic instability in lung cancer tissues by random amplified polymorphic DNA analysis | Q23922200 | ||
| The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors | Q24304941 | ||
| Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization | Q24316003 | ||
| Notch signaling controls multiple steps of pancreatic differentiation | Q24569636 | ||
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. | Q24804951 | ||
| Pancreatic development and disease | Q36720369 | ||
| Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. | Q36787635 | ||
| Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice | Q36999854 | ||
| Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy | Q37127423 | ||
| Extensive pancreas regeneration following acinar-specific disruption of Xbp1 in mice | Q38625919 | ||
| STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. | Q39540918 | ||
| Ras activity levels control the development of pancreatic diseases. | Q39841946 | ||
| A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival | Q39845869 | ||
| Sonic hedgehog promotes desmoplasia in pancreatic cancer | Q39933626 | ||
| A paracrine requirement for hedgehog signalling in cancer | Q39946287 | ||
| Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia | Q40084358 | ||
| Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer | Q40254051 | ||
| Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras | Q40424687 | ||
| Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. | Q42487221 | ||
| K-ras mutations in pancreatic ductal proliferative lesions | Q42753837 | ||
| Primary cilia deletion in pancreatic epithelial cells results in cyst formation and pancreatitis | Q46930897 | ||
| Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. | Q53345254 | ||
| Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer | Q60594558 | ||
| Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult Mice | Q61776577 | ||
| Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms | Q71048246 | ||
| Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis | Q73614651 | ||
| Pancreatic cancer in mice and man: the Penn Workshop 2004 | Q82192931 | ||
| Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings | Q83180835 | ||
| Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours | Q28206040 | ||
| Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors | Q28291740 | ||
| Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes | Q28343950 | ||
| SOX9 is required for maintenance of the pancreatic progenitor cell pool | Q28510325 | ||
| Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway | Q28634556 | ||
| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Q29547558 | ||
| DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis | Q29614217 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis | Q29614405 | ||
| Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 | ||
| Tumor spectrum analysis in p53-mutant mice | Q29617436 | ||
| Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 | ||
| New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. | Q30489770 | ||
| Application of inter-simple sequence repeat PCR to mouse models: assessment of genetic alterations in carcinogenesis | Q30863057 | ||
| Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. | Q33304986 | ||
| Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice | Q33604913 | ||
| Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model | Q33818230 | ||
| KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. | Q33858490 | ||
| Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions | Q34244725 | ||
| Genetics and biology of pancreatic ductal adenocarcinoma. | Q34567515 | ||
| Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse | Q34596182 | ||
| Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver | Q34607172 | ||
| Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras | Q34620985 | ||
| Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma | Q34642090 | ||
| Maximizing mouse cancer models | Q34661270 | ||
| Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma | Q34732306 | ||
| Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. | Q34786695 | ||
| Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas | Q34792019 | ||
| Modelling Myc inhibition as a cancer therapy | Q34811008 | ||
| Hedgehog/Ras interactions regulate early stages of pancreatic cancer | Q35127709 | ||
| Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha | Q35606708 | ||
| Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer | Q36096239 | ||
| Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting | Q36287900 | ||
| Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. | Q36362278 | ||
| In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia | Q36478584 | ||
| The use of targeted mouse models for preclinical testing of novel cancer therapeutics. | Q36603681 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 639-653 | |
| P577 | publication date | 2012-01-09 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice | |
| P478 | volume | 122 |
| Q33671350 | A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice |
| Q36140634 | A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells |
| Q38852413 | A bright future for protein kinase D1 as a drug target to prevent or treat pancreatic cancer |
| Q34729793 | A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer |
| Q37285560 | A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice |
| Q52570601 | A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. |
| Q60309365 | A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model |
| Q91711463 | ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis |
| Q34167517 | Absence of pancreatic intraepithelial neoplasia predicts poor survival after resection of pancreatic cancer. |
| Q49788912 | Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer |
| Q47217864 | Adaptive and reversible resistance to Kras inhibition in pancreatic cancer cells |
| Q34127857 | Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. |
| Q57116328 | Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation |
| Q89285906 | Are Gastric and Esophageal Metaplasia Relatives? The Case for Barrett's Stemming from SPEM |
| Q30843173 | Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers |
| Q40805952 | Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. |
| Q97418367 | Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition |
| Q101120968 | Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer |
| Q94528741 | Black raspberries suppress pancreatic cancer through modulation of NKp46+, CD8+, and CD11b+ immune cells |
| Q36049404 | Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism |
| Q38199723 | Brief overview of selected approaches in targeting pancreatic adenocarcinoma |
| Q42277523 | CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice |
| Q38922372 | CD44 regulates pancreatic cancer invasion through MT1-MMP |
| Q30358993 | CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer. |
| Q37712209 | Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies |
| Q26740619 | Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment |
| Q41777345 | Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer |
| Q39140268 | Canonical wnt signaling is required for pancreatic carcinogenesis |
| Q38730160 | Cellular and molecular aspects of pancreatic cancer |
| Q64099904 | Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development |
| Q37411831 | Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis |
| Q64069077 | Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer |
| Q40989800 | Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. |
| Q36926998 | Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis |
| Q40231669 | Computer-aided diagnostics in digital pathology: automated evaluation of early-phase pancreatic cancer in mice |
| Q103002031 | Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics |
| Q90194029 | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions |
| Q30536268 | Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells |
| Q38124701 | Deciphering the role of stroma in pancreatic cancer |
| Q35612378 | Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer |
| Q37407226 | Diagnosis of pancreatic lesions collected by endoscopic ultrasound-guided fine-needle aspiration using next-generation sequencing |
| Q38815842 | Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer. |
| Q35161464 | Dicer regulates differentiation and viability during mouse pancreatic cancer initiation |
| Q91595228 | Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma |
| Q26748692 | Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review |
| Q61445866 | Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a gene mutation in pancreatic ductal adenocarcinoma |
| Q36698162 | Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. |
| Q41886682 | Dosage-dependent regulation of pancreatic cancer growth and angiogenesis by hedgehog signaling |
| Q41931284 | ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation |
| Q47170368 | Effect of arenobufagin on human pancreatic carcinoma cells |
| Q34566631 | Elevated DNA damage response in pancreatic cancer |
| Q24627664 | Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma |
| Q36922504 | Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu |
| Q37994998 | Energy metabolism and proliferation in pancreatic carcinogenesis |
| Q34895297 | Epithelial Notch signaling is a limiting step for pancreatic carcinogenesis. |
| Q47121552 | Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice. |
| Q47101598 | Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer |
| Q37352098 | Fbxw7 Deletion Accelerates KrasG12D-Driven Pancreatic Tumorigenesis via Yap Accumulation |
| Q26765123 | From bench to bedside a comprehensive review of pancreatic cancer immunotherapy |
| Q38908700 | Functional implication of Dclk1 and Dclk1-expressing cells in cancer. |
| Q26781848 | GEMMs as preclinical models for testing pancreatic cancer therapies |
| Q45234060 | GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice |
| Q38798496 | GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression |
| Q57091632 | Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview |
| Q34657038 | Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine |
| Q88688533 | Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets |
| Q27002973 | Genetically engineered mouse models of pancreatic adenocarcinoma |
| Q36675786 | Genetically engineered mouse models of pancreatic cancer |
| Q54255820 | Genetics and Biology of Pancreatic Ductal Adenocarcinoma. |
| Q26765438 | Genetics and biology of pancreatic ductal adenocarcinoma |
| Q47995755 | Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia. |
| Q26774494 | Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer |
| Q37452148 | Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance |
| Q38749227 | Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. |
| Q36916375 | Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. |
| Q27023576 | Human correlates of provocative questions in pancreatic pathology |
| Q36905828 | Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway |
| Q38824973 | IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. |
| Q90427030 | IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis |
| Q39163078 | IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. |
| Q99576041 | Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer |
| Q57826813 | Image-Based Profiling of Patient-Derived Pancreatic Tumor-Stromal Cell Interactions Within a Micropatterned Tumor Model |
| Q42128007 | Immune cells in pancreatic cancer: Joining the dark side |
| Q28069864 | Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma |
| Q38673158 | Immunotherapy for pancreatic cancer: present and future |
| Q55516479 | Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment. |
| Q38864070 | Inflammation as a driver and vulnerability of KRAS mediated oncogenesis |
| Q39008845 | Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. |
| Q27321370 | Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts |
| Q46357957 | Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression. |
| Q57263190 | Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes |
| Q28504893 | Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance |
| Q41070965 | Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer |
| Q38041420 | Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents |
| Q37048751 | In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status |
| Q34406302 | K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo |
| Q30250097 | K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis |
| Q38731776 | K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target? |
| Q26751520 | KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment |
| Q57463782 | KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation |
| Q46471150 | KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops |
| Q47563012 | KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer |
| Q38175666 | KRAS: feeding pancreatic cancer proliferation |
| Q60925516 | KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer |
| Q38998161 | Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo |
| Q34659332 | Kras as a key oncogene and therapeutic target in pancreatic cancer |
| Q89525914 | Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients |
| Q38909404 | Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. |
| Q37483925 | Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells. |
| Q92040048 | Long noncoding RNA TP53TG1 promotes pancreatic ductal adenocarcinoma development by acting as a molecular sponge of microRNA-96 |
| Q41251358 | Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment |
| Q39356534 | Lung cancer samples preserved in liquid medium: One step beyond cytology |
| Q33680759 | MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice |
| Q36781119 | MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways |
| Q39766565 | Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression |
| Q37071752 | Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. |
| Q47285433 | Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth |
| Q36264967 | Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis |
| Q55516473 | Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism. |
| Q37671861 | Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer |
| Q38829774 | Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation. |
| Q38423050 | Metabolic Dependencies in RAS-Driven Cancers |
| Q38936264 | Metabolic Features of Cancer Treatment Resistance |
| Q38366834 | Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze |
| Q34506422 | Metastatic pancreatic cancer is dependent on oncogenic Kras in mice |
| Q90312107 | MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential |
| Q57282078 | MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells |
| Q33829355 | MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression |
| Q96431210 | Mir34a constrains pancreatic carcinogenesis |
| Q37585776 | Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis |
| Q38063856 | Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration |
| Q26765241 | Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer |
| Q88801478 | Molecular Pathogenesis of Pancreatic Cancer |
| Q38211357 | Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: an under-appreciated symbiotic relationship |
| Q39235977 | Molecular subtypes in cancers of the gastrointestinal tract |
| Q26774636 | Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies |
| Q37618295 | Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes |
| Q90390640 | Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer |
| Q57456710 | Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer |
| Q89242498 | Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism |
| Q34943207 | Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions |
| Q49788157 | Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. |
| Q92271692 | Myeloid Cell-Derived HB-EGF Drives Tissue Recovery After Pancreatitis |
| Q37600068 | Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer |
| Q38916311 | NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. |
| Q36367008 | NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation |
| Q38021692 | New biomarkers and targets in pancreatic cancer and their application to treatment |
| Q28082487 | Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention |
| Q39156056 | Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation |
| Q30388746 | Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy |
| Q64086685 | Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS |
| Q39178061 | Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. |
| Q42564735 | Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. |
| Q51049205 | Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes. |
| Q34113460 | Oncogenic KRAS signalling in pancreatic cancer |
| Q37166218 | Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels |
| Q34147719 | PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. |
| Q34101017 | PD2/Paf1 depletion in pancreatic acinar cells promotes acinar-to-ductal metaplasia |
| Q89471334 | PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression |
| Q38084846 | PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types |
| Q34616196 | PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice |
| Q38238609 | PI3K/Akt-mediated regulation of p53 in cancer |
| Q92078077 | PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-CateninY654 |
| Q26780372 | Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up |
| Q48594379 | Pancreatic Cancer Screening |
| Q26743482 | Pancreatic Cancer from Molecular Pathways to Treatment Opinion |
| Q55104265 | Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. |
| Q52564462 | Pancreatic HIF2α Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. |
| Q27005724 | Pancreatic cancer |
| Q57423198 | Pancreatic cancer |
| Q34093809 | Pancreatic cancer and its stroma: a conspiracy theory |
| Q48328230 | Pancreatic cancer heterogeneity and response to Mek inhibition |
| Q28083814 | Pancreatic cancer, treatment options, and GI-4000 |
| Q35887099 | Pancreatic cancer, treatment options, and GI-4000. |
| Q50195669 | Pancreatic cancer: Current status and Challenges. |
| Q36886497 | Pancreatic cancer: why is it so hard to treat? |
| Q50118423 | Paracrine Secretion of Transforming Growth Factor β by Ductal Cells Promotes Acinar-to-Ductal Metaplasia in Cultured Human Exocrine Pancreas Tissues. |
| Q47958820 | Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport |
| Q91679857 | Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis |
| Q37589374 | Pathogenesis of pancreatic cancer: lessons from animal models |
| Q35670143 | Pathological and molecular evaluation of pancreatic neoplasms |
| Q39204274 | Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. |
| Q41737306 | Plasticity and dedifferentiation within the pancreas: development, homeostasis, and disease |
| Q90425919 | Plasticity of differentiated cells in wound repair and tumorigenesis, part I: stomach and pancreas |
| Q52670614 | Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma. |
| Q36740739 | Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. |
| Q36337206 | Quantitative evaluation and reversion analysis of the attractor landscapes of an intracellular regulatory network for colorectal cancer |
| Q42911905 | Quo vadis, Kras? |
| Q36398735 | RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies |
| Q52721338 | Ras and Rap1: A tale of two GTPases. |
| Q41637362 | Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked |
| Q42253007 | Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma |
| Q28086849 | Regulation of Cellular Identity in Cancer |
| Q41738818 | Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. |
| Q38815948 | Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. |
| Q42110708 | Reproducible automated phosphopeptide enrichment using magnetic TiO2 and Ti-IMAC. |
| Q26801731 | Reserve stem cells: Differentiated cells reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal tract |
| Q58607971 | Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2 |
| Q34400723 | Risk factors for pancreatic cancer: underlying mechanisms and potential targets |
| Q37617965 | Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer |
| Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
| Q38102106 | Roles for KRAS in pancreatic tumor development and progression |
| Q53229089 | SOX9 regulates ERBB signalling in pancreatic cancer development. |
| Q93037837 | SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma |
| Q47151535 | STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines |
| Q38650250 | Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment |
| Q64274365 | Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers |
| Q102144610 | Senescence Inflames the Pancreatic Tumor Microenvironment |
| Q64890448 | Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. |
| Q27334054 | Silencing Mist1 Gene Expression Is Essential for Recovery from Acute Pancreatitis |
| Q34994908 | Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia |
| Q38753641 | Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions |
| Q42457687 | Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia |
| Q27852155 | Somatic mutations in exocrine pancreatic tumors: association with patient survival |
| Q37273793 | Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia |
| Q38494338 | Stromal biology and therapy in pancreatic cancer: a changing paradigm |
| Q33827708 | Stromal reengineering to treat pancreas cancer |
| Q48611990 | Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers |
| Q38204280 | TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. |
| Q52333009 | Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. |
| Q26751686 | Targeting inflammation in pancreatic cancer: Clinical translation |
| Q48907560 | Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. |
| Q33887034 | Targeting reactive nitrogen species suppresses hereditary pancreatic cancer |
| Q34104152 | Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation |
| Q92048149 | Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors |
| Q27021883 | The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas |
| Q50134163 | The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling. |
| Q26799181 | The Role of nAChR and Calcium Signaling in Pancreatic Cancer Initiation and Progression |
| Q64072877 | The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth |
| Q104795301 | The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer |
| Q35732360 | The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential. |
| Q38310416 | The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal |
| Q52558723 | The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. |
| Q41347759 | The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. |
| Q47373966 | The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription |
| Q38740000 | The renewed battle against RAS-mutant cancers |
| Q34283489 | The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling |
| Q34093776 | Therapeutic options for the management of pancreatic cancer |
| Q57060145 | Therapeutic strategies to target RAS-mutant cancers |
| Q49362150 | Tobacco and alcohol as risk factors for pancreatic cancer |
| Q93334535 | Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28 |
| Q90448164 | Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer |
| Q34364766 | Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma |
| Q61446032 | Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis |
| Q52690264 | U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts. |
| Q47150678 | Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth |
| Q39248906 | Utilizing Salmonella to treat solid malignancies. |
| Q28083091 | Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models |
| Q39406815 | What's new in treatment of pancreatic cancer: a patent review (2010-2017). |
| Q90305359 | YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma |
| Q33943271 | Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer |
| Q42359443 | mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer |
| Q39105813 | miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells |
| Q58760423 | p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation |
Search more.